Please login to the form below

Not currently logged in
Email:
Password:

Robert Freisen joins Ablynx

He will take the role of chief scientific officer, effective March 1

Ablynx, recently acquired by Sanofi, has appointed Robert Freisen to the role of chief scientific officer, who will head the biopharma’s scientific research and technology activities.

He succeeds Dr Antonin de Fougerolles, who left the company last year to become Evox Therapeutics’ chief executive officer.

Freisen has more than 20 years’ experience in the biopharmaceutical industry, leading multiple research and development organisations.

He said: “I have long admired Ablynx and am excited to join the company at such an important time.

“With Ablynx's strong pipeline, platform and technology, I am confident that our talented team will continue to deliver novel products to patients that address unmet medical needs where there are currently limited or no therapeutic options."

He has previously held roles for ProQR Therapeutics, Janssen BioTherapeutics, and MorphoSys.

Dr Edwin Moses, chief executive officer of Ablynx, said: “Robert brings an extensive track record of successfully initiating and executing new drug discovery programmes as well as building strong research organisations.

“We are pleased to have him join our team and lead our company's research activities at such an important and exciting time for Ablynx and we will be able to leverage his critical expertise and proven leadership capabilities as we expand our proprietary Nanobody product pipeline.”

31st January 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Pills
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...

Infographics